<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253565</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00009521</org_study_id>
    <secondary_id>DUMC-3992-05-8R3</secondary_id>
    <secondary_id>ROCHE-DUMC-3992-05-8R3</secondary_id>
    <secondary_id>NOVARTIS-DUMC-3992-05-8R3</secondary_id>
    <secondary_id>CDR0000448905</secondary_id>
    <nct_id>NCT00253565</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Hurwitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving imatinib mesylate&#xD;
      together with capecitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate&#xD;
      when given together with capecitabine in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of imatinib mesylate&#xD;
           when administered with capecitabine in patients with advanced malignant solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the non-dose-limiting toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the clinical activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacogenetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the effect of this regimen on wound angiogenesis in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate pharmacokinetic parameters with clinical toxicity, clinical activity, or&#xD;
           surrogate biomarker activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of imatinib mesylate.&#xD;
&#xD;
      Patients receive oral capecitabine twice daily on days 1-14 and oral imatinib mesylate once&#xD;
      or twice daily on days 1-21. Courses repeat every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of patients receive escalating doses of imatinib mesylate until the maximum tolerated&#xD;
      dose is determined.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumors for which no standard effective&#xD;
             therapy exists OR such therapy is refused&#xD;
&#xD;
          -  Previously treated brain metastases that are currently asymptomatic allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 2,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000 mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No other clinically significant cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy&#xD;
&#xD;
          -  No known sensitivity to fluorouracil&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 28 days since prior biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 28 days since prior chemotherapy (42 days for nitrosoureas or mitomycin C)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 90 days since prior steroids for the treatment of brain metastases&#xD;
&#xD;
          -  More than 28 days since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 90 days since prior radiotherapy for the treatment of brain metastases&#xD;
&#xD;
          -  More than 28 days since other prior radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy &gt; 30% of the bone marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 28 days since prior surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert I. Hurwitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Res. 2010 Apr;30(4):1251-6.</citation>
    <PMID>20530436</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Hurwitz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

